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  DREAM (downstream regulatory element antagonistic modulator) is a calcium-binding protein that 
regulates dynorphin expression, promotes potassium channel surface expression, and enhances 
presenilin processing in an expression level-dependent manner. However, no molecular mechanism has 
yet explained how protein levels of DREAM are regulated. Here we identified group I mGluR 
(mGluR1/5) as a positive regulator of DREAM protein expression. Overexpression of mGluR1/5 
increased the cellular level of DREAM. Up-regulation of DREAM resulted in increased DREAM protein 
in both the nucleus and cytoplasm, where the protein acts as a transcriptional repressor and a 
modulator of its interacting proteins, respectively. DHPG (3,5-dihydroxyphenylglycine), a group I 
mGluR agonist, also up-regulated DREAM expression in cortical neurons. These results suggest that 
group I mGluR is the first identified receptor that may regulate DREAM activity in neurons.
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INTRODUCTION
  Downstream regulatory element antagonistic modulator 
(DREAM) is a calcium-binding protein, and is variously 
known as calsenilin and KChIP3, named according to the 
original binding proteins when discovered independently 
[1]. DREAM acts as a transcriptional repressor of dynor-
phin, a subunit of potassium channels, and a modulator of 
presenilin [2-4]. DREAM binds to a dynorphin response ele-
ment (DRE) upstream of the dynorphin gene, thereby sup-
pressing its expression [2]. It also binds to presenilins and 
regulates the amount of fragmented presenilins [3]. DREAM 
interaction with the A-type potassium channel (carboxyl 
terminus) is reported to be essential for proper channel 
function [4]. Among these, the most studied mechanism of 
DREAM action is the regulation of nociception by modulat-
ing dynorphin expression. DREAM binding to DRE is in-
hibited by increased calcium, possibly due to its binding 
to the calcium-binding motifs of the protein, suggesting the 
presence of a calcium-mediated regulatory mechanism of 
DREAM activity [5]. DREAM knockout mice show in-
creased expression of dynorphin in the spinal cord and, ac-
cordingly, decreased sensitivity to pain [2]. 
  Most of the roles of DREAM have been explored based 
on overexpression and knockout experiments of the 
DREAM gene, and alteration in the levels of DREAM have 
been shown to result in changes in various cell functions 
[2-4]. However, very little information concerning the phys-
iological regulatory mechanism of DREAM levels in cells 
is available. The only finding we have is that amyloid β 
(Aβ) increased expression of DREAM in cultured neurons 
[6]. Furthermore, in addition to the regulation of expression 
level of the molecule, DREAM must be localized to the nu-
cleus to act as a repressor of dynorphin transcription. 
Calcium ionophore, thapsigargin, and serum starvation 
were reported to promote nuclear localization of DREAM 
[7,8]. However, little information is available about the sig-
naling proteins or receptors that affect the subcellular local-
ization of DREAM.
  Metabotropic glutamate receptor 5 (mGluR5) and mGluR1 
are members of the metabotropic glutamate receptor family 
of G protein-coupled receptors (GPCRs), which has 8 sub-
types. mGluR5 has long been known to be implicated in 
the regulation of synaptic transmission and synaptic plasti-
city [9]. mGluR5 is also involved in neurological and psychi-
atric diseases such as anxiety, addiction, pain, and fragile 
X mental retardation syndrome [9-13]. At the molecular 
level, group I mGluR (comprised of mGluR1 and mGluR5) 
has been reported to interact or regulate calcium-binding 
proteins, such as the neuronal calcium sensors NCS-1 
(neuronal calcium sensor-1) and VILIP-1 (visinin-like pro-
tein-1) [14]. We therefore hypothesized that mGluR1/5 may 
be a group of receptors that can relay extracellular signals 
to regulate the activity of DREAM, another member of the 
neuronal calcium sensor family of proteins.
  Here we tested whether a functional interaction between 
mGluR1/5 and DREAM is present, and the consequence of 
this interaction. We report that group I mGluR up-regu-
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lates protein levels of DREAM and accumulates the protein 
in the nucleus and cytoplasm. These results suggest group 




  His-tagged rat DREAM was expressed in BL21 (DE3), pu-
rified with nickel-resin, and used for anti-DREAM antibody 
production. Commercial murine monoclonal anti-DREAM 
antibody (Millipore, Billerica, MA, USA) was also used. 
Monoclonal anti-His and anti-Myc antibodies were pur-
chased from BD Biosciences (San Diego, CA, USA) and 
Sigma-Aldrich (St. Louis, MO, USA), respectively. EDTA- 
AM was purchased from Molecular Probes (Eugene, OR, 
USA). Unless otherwise noted, all other reagents were pur-
chased from Sigma-Aldrich.
Constructs
  Chicken β-actin promoter replaced the CMV promoter 
of the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA), gen-
erating a pCBA vector. The coding region of rat DREAM 
was amplified with PCR and inserted into pcDNA3.1 His 
C and pCBA at the EcoRI site. The D150N, E186Q, and 
E234Q mutations were introduced for disabling Ca2＋ bind-
ing to EF hand 2, 3, and 4, respectively, by site-directed 
mutagenesis with the primers: 5'-CCA TCC ACT TTG AGA 
ACT TTG TGG TTG GGC-3' and 5'-GCC CAA CCA CAA 
AGT TCT CAA AGT GGA TGG 3' for D150N, 5'- CAT CAC 
CAA AGA GCA GAT GCT GGC CAT C-3' and 5'-GAT GGC 
CAG CAT CTG CTC TTT GGT GAT G-3' for E186Q, and 
5'-GGA GTA GTG ACT ATT GAT CAA TTT CTG GAG ACT 
TGT C-3' and 5'-GAC AAG TCT CCA GAA ATT GAT CAA 
TAG TCA CTA CTC C-3' for E234Q [15]. Multiple mutant 
constructs, QQ and NQQ, were made by sequential muta-
genesis. The cDNA of mGluR5 was inserted into the pRK5. 
F767S mutant of mGluR5, which corresponds to F781S or 
Gαq protein binding mutant of mGluR1, and was made with 
5’-AGA AAT GTT CCA GCC AAC TCT AAT GAG GCC AAA 
TAT ATT-3’ and 5’-AAT ATA TTT GGC CTC ATT AGA GTT 
GGC TGG AAC ATT TCT-3’ [16].
Cell culture
  HEK293, HeLa, and SK-N-MC cells were obtained from 
ATCC (Manassas, VA, USA). All cells were cultured in 
Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, 
CA, USA) containing 10 mM L-glutamine, 100 U/ml pen-
icillin, 0.1 mg/ml streptomycin, and 10% fetal bovine serum. 
Cells were maintained in 5% CO2/95% air atmosphere at 
37oC.
  Primary cortical neuron cultures are described elsewhere 
[17]. Briefly, the meninges were removed from brains of 
TP18 Sprague Dawley rats with fine forceps. Isolated corti-
ces were minced, trypsinized, and triturated through a 
Pasteur pipette narrowed by flame. The resulting cell sus-
pensions were counted and plated onto 6-well plates coated 
with poly-L-ornithine and fibronectin. Cultures were main-
tained in neurobasal medium (Invitrogen, Carlsbad, CA, 
USA) with B-27 supplement (Invitrogen, Carlsbad, CA, 
USA).
Cell fractionation
  Cells were washed with PBS and pelleted by cen-
trifugation followed by swelling in low salt buffer contain-
ing 20 mM HEPES pH 7.9, 1.5 mM MgCl2, and protease 
inhibitor cocktail. Swollen cells were lysed with syringe ho-
mogenization and centrifuged at 3,000 g for 3 min. Triton 
X-100 (1%) was added to the supernatant for cytoplasmic 
extraction. The resulting pellet was washed twice with low 
salt buffer and incubated in high salt buffer (low salt buffer 
supplemented with 420 mM KCl) for nuclear protein 
extraction. 
Western blot analysis
  Cells were plated onto 6-well plates at 1×105 to 2×105 
per well for 18 h and transfected with Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). After 36 h of incubation, 
cells were pelleted; lysed with denaturing lysis buffer con-
taining 10 mM Tris, 2% SDS pH 7.4, and Complete Protea-
se Inhibitor Cocktail (Roche, Indianapolis, IN, USA); boiled 
for 10 min; and cleared with centrifugation at 13,000 g for 
10 min. Cell lysates were separated by 10% SDS-PAGE and 
transferred onto nitrocellulose membranes. The membrane 
was blocked with 5% non-fat milk and probed with primary 
and horseradish peroxidase (HRP)-conjugated secondary 
antibodies followed by chemiluminescence detection with 
an ECL (Pierce, Rockford, IL, USA) in LAS-4000 CCD cam-
era (GE Healthcare, Piscataway, NJ).
Immunostaining
  pCBA-DREAM was co-transfected with pRK5 or pRK5- 
myc-mGluR5 into HEK293 cells, which were grown for 18 
h after being plated onto cover slips. After further in-
cubation for 36 h following transfection, cells were washed 
with PBS, fixed with 4% paraformaldehyde for 5 min, and 
blocked with goat serum. The cells on the cover slips were 
treated with rabbit anti-DREAM and anti-Myc antibodies, 
rinsed with PBS, and incubated with Alexa 488- and Alexa 
568-conjugated secondary antibodies. Cells were observed 
under a Zeiss LSM710 confocal microscope (Jena, Germany).
RESULTS
Group I mGluR increases protein levels of DREAM
  To investigate the possible functional interaction between 
mGluR5 and DREAM, HEK293 cells were transfected with 
mGluR5 and DREAM, and expression of DREAM was ana-
lyzed using Western blotting. The expression of DREAM 
was increased by mGluR5 (Fig. 1A). Transfection of mGluR5 
in the SK-N-MC neuroblastoma cell line that expresses en-
dogenous DREAM also promoted an increase in DREAM 
(Fig. 1B). Next we tested whether G protein coupled to 
mGluR5 is required for the effect of the receptor on the 
level of DREAM. HEK293 cells were transfected with 
DREAM and wild-type mGluR5 or mGluR5 F767S, a muta-
nt incapable of G protein coupling [16]. Wild-type mGluR5 
increased DREAM expression whereas the mGluR5 F767S 
mutant did not, suggesting that G protein mediated the ef-
fect of mGluR5 on the levels of DREAM (Fig. 1C). To con-
firm that mGluR5 activity is involved in the modulation 
of DREAM, we treated cells expressing mGluR5 and 
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Fig. 1. Group I mGluR increases DREAM protein expression. (A, C, and D∼F) HEK293 cells were co-transfected with 500 ng of each 
plasmid expressing DREAM or hippocalcin and 50 ng of pRK5 empty vector, pRK5-mGluR subtypes, or pRK5-mGluR5 F767S (Gαq binding 
site mutant of mGluR5). Cell lysates were immunoblotted with rabbit anti-DREAM or anti-hippocalcin antibody. (B) pRK5 or pRK5-mGluR5 
(200 ng) was transfected into SK-N-MC cells for 36 h before cell lysis. Immunoblotting using mouse anti-DREAM antibody was performed.
(E) Cells were treated with MPEP for 15 h before lysis. Lysis was performed by boiling with denaturing lysis buffer after 36 h of cultivation.
WT, wild-type.
Fig. 2. mGluR5 stabilizes DREAM protein. (A) pCBA-DREAM was 
co-transfected with pRK5 or pRK5-mGluR5 into HEK293 cells. 
Cells were lysed after 48 h of incubation. Cells were treated with
cycloheximide (CHX) at 100 μg/ml for 0, 2, 4, 6, or 8 h before cell 
lysis. DREAM expression was analyzed by immunoblotting with 
rabbit anti-DREAM antibody. (B) HEK293 cells were transfected 
as indicated above. EDTA-AM (100 nM) was added to culture for 
12 h to chelate intracellular Ca2＋. Immunoblotting was performed
using rabbit anti-DREAM antibody. (C) Lysates from cells 
expressing mGluR5 and DREAM (E186Q/E234Q) double mutant or 
DREAM (D150N/E186Q/E234Q) triple mutant were subjected to 
Western blotting.
DREAM with MPEP (2-Methyl-6-(phenylethynyl)pyridine 
hydrochloride), a specific mGluR5 antagonist, for 15 h. 
MPEP inhibited the effect of mGluR5 on the levels of 
DREAM, indicating that constitutive activity of mGluR5 
overexpressed in HEK293 cells increased the expression of 
DREAM (Fig. 1D). mGluRs are composed of eight subtypes 
and sub-classified into groups I, II, and III according to li-
gand specificity, sequence homology, and G protein coupl-
ings. The group I mGluRs (mGluR1 and mGluR5) couple 
to Gαq protein and the group II mGluRs (mGluR2 and 
mGluR3) and the group III mGluRs (mGluR4, 6, 7, 8) cou-
ple to Gαi/o proteins [9]. We examined whether the up-regu-
lation of DREAM by a metabotropic glutamate receptor is 
specific to the mGluR5 subtype. Cells were co-transfected 
with DREAM and mGluR1, 2, 3, or 7 and changes in 
DREAM levels were measured using Western blot analysis. 
Among the mGluR subtypes tested, only mGluR1 pro-
foundly increased DREAM expression, suggesting that only 
group I mGluRs can regulate the levels of DREAM (Fig. 
1E). We also tested the effect of mGluR5 on hippocalcin, 
a protein belonging to the neuronal calcium sensor family 
[18], the same family as DREAM. mGluR5 did not increase 
the level of hippocalcin in cells co-expressing mGluR5 and 
hippocalcin (Fig. 1F), indicating that the effect of mGluR5 
is not generalized toward all neuronal calcium sensor fam-
ily proteins. 
Stabilization of DREAM by mGluR5
  There are several potential mechanisms by which mGluR5 
increases the level of DREAM in cells. Perhaps the simplest 
prediction is that mGluR5 could increase the stability of 
DREAM. Thus, we tested the hypothesis that mGluR5 en-
hanced the stability of DREAM. HEK293 cells were 
co-transfected with DREAM alone or mGluR5 and DREAM 
and pre-treated with cycloheximide for 8 h. The protein lev-
els of DREAM at each time point (0, 2, 4, 6, and 8 h) were 
measured using Western blot analysis. Sustained levels of 
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Fig. 3. Subcellular localization of increased DREAM by mGluR5. 
(A) pCBA-DREAM and/or pRK5-myc-mGluR5 were transfected into 
HeLa cells. Following 36 h incubation, cells were fixed with 4% 
paraformaldehyde, blocked with goat serum, and incubated with 
rabbit anti-DREAM and anti-myc antibody. After incubation, fixed 
cells were washed and treated again with Alexa 488 anti-rabbit 
and Alexa 568 anti-mouse antibodies. Images were obtained under 
a Zeiss LSM 710 confocal microscope. (B) HEK293 cells were co- 
transfected with pRK5-mGluR5 and pCBA-DREAM. Cytoplasmic 
and nuclear extracts were prepared from transfected cells. Western 
blotting was performed to determine the amount of DREAM in each 
fraction.
Fig. 4. DHPG increases DREAM levels in primary cultured 
neurons. Primary cultures of rat cortical neurons were prepared 
from 17-day-old embryonic brains. At day 12 in vitro, neurons were 
treated with 200 μM DHPG for 12 h. Changes in DREAM level 
were measured using Western blot analysis. 
DREAM were observed over time in cells expressing both 
mGluR5 and DREAM compared to cells expressing DREAM 
alone (Fig. 2A). This result suggests that mGluR5 increases 
the levels of DREAM by enhancing the stability of the 
protein. Because DREAM is a calcium-binding protein and 
has typical calcium-binding motifs, we investigated wheth-
er calcium chelation or mutation of calcium-binding motifs 
had any effect on the stability of DREAM. We performed 
Western blotting in lysates from cells transfected with 
mGluR5 and DREAM, followed by administration of EDTA- 
AM (disodium ethyldiamine tetraacetic acid-acetoxymethyl 
ester) for 12 h. EDTA-AM decreased the level of DREAM, 
indicating that intracellular calcium is required for the 
mGluR5 signaling responsible for the regulation of DREAM 
levels (Fig. 2B). To determine the effects of mutations in 
calcium-binding motifs on the stability of DREAM, cells 
were transfected with mGluR5 and DREAM mutants 
(E186Q/E234Q mutant and D150N/E186Q/E234Q mutant), 
which have been reported to disrupt calcium binding [15]. 
We observed that no mutants abolished the effect of 
mGluR5 on their expression levels, suggesting no involve-
ment of calcium-binding motifs of DREAM in mGluR5 regu-
lation of the protein (Fig. 2C).
mGluR5 increases DREAM protein in both the nucleus 
and cytoplasm
DREAM binding to the DRE region in the promoter of the 
dynorphin gene and consequent repression of dynorphin 
transcription is a well-known mechanism by which DREAM 
modulates nociception. To test whether the mGluR5-in-
duced increase in DREAM expression caused accumulation 
of the protein in the nucleus, we transfected HeLa cells 
with mGluR5 and DREAM and performed immunofluor-
escence. We observed that mGluR5 promoted the nuclear 
localization of DREAM, as shown by a prominent increase 
in DREAM immunofluorescence in the nucleus (Fig. 3A). 
HEK293 cells were transfected with mGluR5 and DREAM 
and fractionated into the nucleus and cytoplasm. In 
Western blot analysis, mGluR5 increased the level of 
DREAM in both the cytoplasm and the nucleus of HEK293 
cells expressing mGluR5 and DREAM (Fig. 3B). These re-
sults suggest that mGluR5 can promote the localization of 
DREAM in the nucleus, where it acts as a transcriptional 
repressor, and also increase the amount of DREAM in the 
cytoplasm, where it can interact with binding partners such 
as presenilin and channels.
Increase in the protein level of DREAM by DHPG in 
primary cultured cortical neurons
  To investigate whether mGluR1/5-induced regulation of 
DREAM can also occur in primary cultured neurons, where 
group I mGluR and DREAM are naturally expressed, we 
prepared primary cultures of cortical neurons and treated 
cells with DHPG (3,5-dihydroxyphenylglycine), a group I 
mGluR agonist, for 12 h at day 12 in vitro. DHPG increased 
the level of DREAM in primary cultured cortical neurons 
(Fig. 4), suggesting that agonist-induced activation of en-
dogenous group I mGluR in neurons contributes to the reg-
ulation of DREAM. 
DISCUSSION
  The present investigation demonstrates that group I 
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mGluR is a group of receptor that can regulate the protein 
level of DREAM. mGluR1/5 signaling is mainly mediated 
by Gαq protein-coupled mediators, although many G pro-
tein-independent signaling pathways have been increas-
ingly reported [19,20]. The finding that the mGluR5 F767S 
mutant could not increase the level of DREAM protein sug-
gests that DREAM stabilization by mGluR5 is mediated by 
Gαq protein-initiated signaling. This was further supported 
by the result that intracellular chelation of calcium, an im-
portant downstream second messenger of Gαq signaling, 
prevented the up-regulation of DREAM by mGluR5. 
mGluR1 is another group I mGluR coupled to Gαq protein. 
Unlike the group II and group III mGluRs, mGluR1 induced 
an increase in DREAM level, which also supports the in-
volvement of a Gαq protein-mediated signaling mechanism. 
Although it is evident that mGluR5 regulates the stability 
of DREAM, the underlying mechanism remains unclear. 
mGluR5 up-regulates NCS-1 and VILIP protein levels in 
the hippocampus in vivo [14]. However, the protein stabil-
ities or mRNA expressions were not measured. Interesting-
ly, hippocalcin, a neuronal calcium sensor protein, was not 
affected by mGluR5 in our study. Thus, it seems that 
mGluR5-dependent regulation of neuronal calcium sensor 
proteins is not a universal phenomenon for all calci-
um-binding proteins that have characteristics of EF-hand 
calcium-binding domains in common. Domain study for 
DREAM suggests that the C-terminal portion of the protein 
is involved in the stabilization mechanism by mGluR5 (data 
not shown), suggesting that certain specific mechanisms 
might be present for the regulation of DREAM by calcium 
levels elicited by mGluR5. This finding suggests a need for 
further study.
  The important roles of DREAM are implicated in the 
modulation of pain, regulation of neuronal excitability, and 
pathogenesis of Alzheimer disease [1,3,4,21]. The sites of 
actions of DREAM can be divided into two locations: near 
the membrane and inside the nucleus. DREAM regulation 
of Kv channels and gamma-secretase may occur near the 
membrane, and DREAM suppression of dynorphin expres-
sion takes place in the nucleus. The mGluR5-induced in-
crease in DREAM in the cytoplasm, and more prominent 
increase in the nucleus, indicates the potential enhance-
ment of DREAM functions in both regions. Probably, the 
specific cellular context of certain cell types stimulated by 
mGluR5 would be an important factor that determines the 
discernible phenotype of DREAM up-regulation. 
  mGluR5 has been implicated in various neurological and 
psychiatric diseases, including anxiety, depression, pain, 
and Alzheimer disease [9,10]. mGluR5 has also long been 
related to pain, since mGluR5 antagonists such as MPEP 
and MTEP (3-((2-Methyl-4-thiazolyl)ethynyl)pyridine) re-
lieve pain in several animal models, and conditional 
mGluR5 knockout in the central nucleus of the amygdala 
results in the diminution of inflammation-induced hyper-
sensitivity [22-24]. Interestingly, the analgesic effect of 
mGluR5 is reported to be mediated by its extracellular sig-
nal-regulated kinase-linked interaction with Kv4.2, the po-
tassium channel regulated by DREAM [25]. DREAM regu-
lation of dynorphin induction is one of the well-known 
mechanisms of pain regulation [2,21]. Taken together, these 
reports suggest an intriguing possibility that the mGluR5- 
mediated increase in DREAM in both the cytoplasm and 
nucleus may contribute to pronociceptive functions of 
mGluR5. We have demonstrated that mGluR5 increased 
the protein level of DREAM in both compartments. Hence, 
research toward a better understanding of the role of stabi-
lized DREAM in the physiology of neurons and the patho-
physiology of pain and Alzheimer disease may allow for the 
development of new treatments.
  In conclusion, group I mGluR stabilize the DREAM pro-
tein, suggesting a potential link between mGluR5, DREAM, 
and neuronal dysfunctions in pain and Alzheimer disease.
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